Bionas GmbH has announced that it closed a € 2.1 million financing deal to fund sales, marketing and product expansion. GENIUS Venture Capital GmbH and the KfW-Bankengruppe (ERP-Startfonds) participated in the financing.
Additionally, the Federal Ministry of Education and Research, Germany (BMBF) and the Federal State of Mecklenburg-Vorpommern (Ministry of Economics) granted subsidies of undisclosed amounts for two development projects.
“The new funding allows us to expand the sales and marketing of Bionas ® analyzing systems throughout Europe and the US,” says Dr. Ralf Ehret, CEO and co-founder of Bionas. “We will also boost technical innovations for novel products and applications to assure the continuous growth of the company.”
The Bionas® 2500 analyzing system, the company´s main product, gives a complete overview of the physiologic state of cells. It can be used to analyze different signal transduction pathways, allowing target validation studies at an early stage in the drug discovery process. Recently, Bionas announced that its device has been selected by Solvay Pharmaceuticals for target validation studies.